Bates SE. Epigenetic therapies for cancer. N Engl J Med. 2020;383(7):650–63.

Article  CAS  PubMed  Google Scholar 

Sun S, Yu F, Xu D, et al. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy. BBA Rev Cancer. 2022. https://doi.org/10.1016/j.bbcan.2022.188700.

Article  Google Scholar 

Izutsu K, Makita S, Nosaka K, et al. An open-label, single-arm, phase 2 trial of valemetostat in relapsed or refractory adult T-cell leukemia/lymphoma. Blood. 2022. https://doi.org/10.1182/blood.2022016862.

Article  PubMed  Google Scholar 

Kusumoto S, Izutsu K, Maruyama D, et al. First-in-human study of the EZH and EZH2 dual inhibitor valemetostat tosylate (DS-3201B) in patients with relapsed or refractory non-Hodgkin lymphomas [abstract no. S218]. In: 26th Congress of the European Haematology Association. 2021.

Yamagishi M, Hori M, Fujikawa D, et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019;29(8):2321-37.e7.

Article  CAS  PubMed  Google Scholar 

Nakagawa M, Kitabayashi I. Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies. Cancer Sci. 2018;109(8):2342–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lymphoma Research Foundation. About lymphoma and subtypes. 2021. https://lymphoma.org/. Accessed 13 Oct 2022.

Zhuang Y, Che J, Wu M, et al. Altered pathways and targeted therapy in double hit lymphoma. J Hematol Oncol. 2022. https://doi.org/10.1186/s13045-022-01249-9.

Cook LB, Fuji S, Hermine O, et al. Revised adult T-cell leukemia-lymphoma International Consensus Meeting report. J Clin Oncol. 2019;37(8):677–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daichii-Sankyo Company Ltd. EZHARMIA® (valemetostat tosilate): Japanese prescribing information. 2022. https://www.pmda.go.jp/PmdaSearch/iyakuSearch/. Accessed 28 Sept 2022.

Daiichi Sankyo Company Ltd. Daiichi Sankyo's EZH1/2 dual inhibitor valemetostat (DS-3201) receives SAKIGAKE designation for treatment of patients with relapsed/refractory peripheral T-cell lymphoma from Japan MHLW [media release]. 9 Apr 2019. http://www.daiichisankyo.com.

Daiichi Sankyo Company Ltd. EZHARMIA® approved in Japan as first dual EZH1 and EZH2 inhibitor therapy for patients with adult T-cell leukemia/lymphoma [media release]. 26 Sep 2022. https://www.daiichisankyo.com/.

Daiichi Sankyo Company Ltd, LYSA-LYSARC-CALYM. Daiichi Sankyo and LYSA-LYSARC-CALYM enter research collaboration for valemetostat in patients with relapsed/refractory B-Cell lymphoma [media release]. 24 Feb 2021. https://daiichisankyo.us/.

Daiichi Sankyo Company Ltd, The University of Texas MD Anderson Cancer Center. MD Anderson and Daiichi Sankyo enter research collaboration to accelerate development of acute myeloid leukemia therapies [media release]. 14 Sep 2017. http://www.daiichisankyo.com.

Honma D, Adachi N, Kanno O, et al. Development and characterization of the novel orally bioavailable EZH1/2 dual inhibitor DS-3201 [abstract no. 2073]. Blood. 2017;130(Suppl 1).

Honma D, Kanno O, Watanabe J, et al. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. Cancer Sci. 2017;108(10):2069–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Honma D, Nosaka E, Shiroishi M, et al. DS-3201, a potent EZH1/2 dual inhibitor, demonstrates antitumor activity against non-Hodgkin lymphoma (NHL) regardless of EZH2 mutation [abstract no. 2217]. Blood. 2018;132 (Suppl. 1).

Banjo T, Hama Y, Nosaka E, et al. EZH1/2 dual inhibitor valemetostat tosylate (DS-3201b) acts differently from EZH2 selective inhibitor on epigenetic landscape to exert greater anti-tumor effect against diffuse large B-cell lymphoma [abstract no. 2948]. Blood. 2021;138(Suppl. 1 ).

Fujita S, Honma D, Adachi N, et al. Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia. Leukemia. 2018;32(4):855–64.

Article  CAS  PubMed  Google Scholar 

Hama Y, Banjo T, Honma D, et al. Anti-tumor effect of the EZH1/2 dual inhibitor valemetostat against diffuse large B-cell lymphoma via modulation of B-cell receptor signaling and c-Myc signaling pathways [abstract no. 4642]. Blood. 2019;134(Suppl 1).

Yamagishi M, Hori M, Fujikawa D, et al. Development and molecular analysis of synthetic lethality by targeting EZH1 and EZH2 in non-Hodgkin Lymphomas [abstract no. 462]. Blood. 2016;128(22).

Tachibana M, Maekawa Y, Matsuki S, et al. Open-label study to evaluate the effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat tosylate (valemetostat, DS-3201b) in healthy participants [abstract no. P-175]. Clin Pharmacol Ther. 2022;111(Suppl S1):S51-2.

Daiichi Sankyo Company Ltd. Valemetostat data at EHA shows promising durable tumor response in patients with peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma [media release]. 11 Jun 2021. http://www.daiichisankyo.com.

Foss FM, Porcu P, Horwitz SM, et al. A global phase 2 study of valemetostat tosylate (valemetostat) in patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL), including R/R adult T-cell leukemia/lymphoma (ATL)—Valentine-PTCL01 [abstract no. 2533]. Blood. 2021;138(Suppl. 1).

Arakawa A, Ozawa H, Hirakawa A, et al. Trial in progress: a phase I trial of dual EZH 1/2 inhibitor valemetostat tosylate (DS- 3201b) in pediatric, adolescent, and young adult patients with malignant solid tumors [abstract no. TPS10059]. J Clin Oncol. 2022;40 (16 Suppl).